Use of anti-cd40 antibodies for treatment of lupus nephritis
AssigneeBoehringer Ingelheim International GmbH
InventorsScott Ronald BRODEUR, Thomas B. FREEMAN, Gerald Henry Nabozny, Meera RAMANUJAM, Paul SCHOLL, Juergen STEFFGEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.
Claims10
A method of treating or preventing lupus nephritis, the method comprising administering to a human patient in need thereof a therapeutically effective amount of a humanized antibody that specifically binds human CD40, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
- a) a heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO:
- 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17;
- and
- b) the light chain CDR1 sequence has a sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:22 through SEQ ID NO:23, and a light chain CDR3 sequence selected from the group consisting of SEQ ID NO:24 through SEQ ID NO:25.
A method of treating or preventing lupus nephritis, the method comprising administering to a human patient in need thereof a therapeutically effective amount of a humanized monoclonal antibody or antibody fragment that specifically binds human CD40, said antibody or antibody fragment having a heavy chain variable domain and a light chain variable region comprising the amino acid sequences selected from:
- SEQ ID NO:27 and SEQ ID NO:26, respectively;
- SEQ ID NO:28 and SEQ ID NO:26, respectively;
- SEQ ID NO:29 and SEQ ID NO:26, respectively;
- SEQ ID NO:30 and SEQ ID NO:26, respectively;
- SEQ ID NO:32 and SEQ ID NO:31, respectively;
- SEQ ID NO:33 and SEQ ID NO:31, respectively;
- SEQ ID NO:34 and SEQ ID NO:31, respectively;
- SEQ ID NO:35 and SEQ ID NO:31, respectively;
- SEQ ID NO:37 and SEQ ID NO:36, respectively;
- SEQ ID NO:38 and SEQ ID NO:36, respectively;
- SEQ ID NO:39 and SEQ ID NO:36, respectively;
- SEQ ID NO:40 and SEQ ID NO:
- 36, respectively;
- SEQ ID NO:
- 44 and SEQ ID NO:
- 43, respectively;
- SEQ ID NO:
- 53 and SEQ ID NO:
- 52, respectively;
- and
- SEQ ID NO:
- 58 and SEQ ID NO:
- 56, respectively.
(canceled)
A pharmaceutical composition comprising
- (a) a humanized antibody that specifically binds human CD40, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
- i) the heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO:
- 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17;
- and
- ii) the light chain CDR1 sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:22 through SEQ ID NO:23, and a light chain CDR3 sequence selected from the group consisting of SEQ ID NO:24 through SEQ ID NO:25;
- and
- (b) a buffer, a stabilizing agent, and, optionally, a pH adjusting agent.
Dependencies are inferred from the claim text.